FSHD research teams in Seattle, Rochester and Leiden add to the existing FSHD model loss of heterochromatin at D4Z4 and the presence of a specific haplotype on chromosome 4 are necessary but not sufficient for DUX4 expression in PLoS ONE. Choice of transcriptional direction from each D4Z4 unit is an additional requirement for DUX4 production… Read More »
FSH Society grantees publish new paper “RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy” in The American Society of Gene & Cell Therapy providing proof-of-principle for RNAi therapy of FSHD through DUX4 inhibition
New paper in Developmental Cell identifies a set of genes regulated by DUX4 and suggests possible mechanisms for causing muscle damage that might be targeted for developing therapies “DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for FSHD”
Best practice guidelines on genetic diagnostics of FSHD are now available and published in the journal Neuromuscular Disorders! FSH Society sponsors workshop held June 9, 2010, in Leiden, The Netherlands.
Our 2011 annual review of scientific research funded by the FSH Society was published in the Summer 2011 issue of the FSH Watch newsletter. The issue includes a list of the top papers from the year with comments about their significance, opportunities for research volunteers, and the latest Society news from 2011. The full issue is available here to… Read More »